CN103180319A - 氨基脲敏感性胺氧化酶抑制剂 - Google Patents

氨基脲敏感性胺氧化酶抑制剂 Download PDF

Info

Publication number
CN103180319A
CN103180319A CN2011800140213A CN201180014021A CN103180319A CN 103180319 A CN103180319 A CN 103180319A CN 2011800140213 A CN2011800140213 A CN 2011800140213A CN 201180014021 A CN201180014021 A CN 201180014021A CN 103180319 A CN103180319 A CN 103180319A
Authority
CN
China
Prior art keywords
alkyl
compound
amino
pyridin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800140213A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·埃文斯
阿莉森·卡利
阿莉森·斯图尔特
迈克尔·希金博特姆
爱德华·萨沃里
伊恩·辛普森
玛丽安娜·尼尔森
马丁·哈拉尔德松
埃里克·努德林
托比亚斯·科尔迈斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Cambridge Ltd
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of CN103180319A publication Critical patent/CN103180319A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
CN2011800140213A 2010-03-15 2011-03-14 氨基脲敏感性胺氧化酶抑制剂 Pending CN103180319A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1004311.5 2010-03-15
GBGB1004311.5A GB201004311D0 (en) 2010-03-15 2010-03-15 New enzyme inhibitor compounds
PCT/EP2011/053818 WO2011113798A2 (en) 2010-03-15 2011-03-14 New enzyme inhibitor compounds

Publications (1)

Publication Number Publication Date
CN103180319A true CN103180319A (zh) 2013-06-26

Family

ID=42261625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800140213A Pending CN103180319A (zh) 2010-03-15 2011-03-14 氨基脲敏感性胺氧化酶抑制剂

Country Status (17)

Country Link
US (1) US9227967B2 (https=)
EP (2) EP2927233A1 (https=)
JP (2) JP5643347B2 (https=)
KR (1) KR20130057971A (https=)
CN (1) CN103180319A (https=)
AU (1) AU2011229267B2 (https=)
BR (1) BR112012023315A2 (https=)
CA (1) CA2793125A1 (https=)
DK (1) DK2547677T3 (https=)
EA (1) EA023038B1 (https=)
ES (1) ES2538526T3 (https=)
GB (1) GB201004311D0 (https=)
MX (1) MX2012010292A (https=)
NZ (1) NZ602141A (https=)
SG (1) SG183936A1 (https=)
WO (1) WO2011113798A2 (https=)
ZA (1) ZA201206424B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106045876A (zh) * 2016-06-07 2016-10-26 四川福思达生物技术开发有限责任公司 一种对氯苯肼盐酸盐的合成方法
CN107074854A (zh) * 2014-09-17 2017-08-18 普罗克斯马根有限公司 咪唑并[4，5‑c]吡啶衍生的SSAO抑制剂
CN107074853A (zh) * 2014-09-17 2017-08-18 普罗克斯马根有限公司 咪唑并[4,5‑c]吡啶衍生的SSAO抑制剂
CN110325533A (zh) * 2016-09-16 2019-10-11 生命医药有限责任公司 Menin-mll相互作用的抑制剂

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2755974A1 (en) * 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
EP3438087A1 (en) 2012-05-02 2019-02-06 Boehringer Ingelheim International GmbH Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
US20150291606A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
KR102412146B1 (ko) * 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
GB201507031D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd New pharmaceutical salt forms
HK1256174A1 (zh) 2015-12-07 2019-09-13 Benevolentai Cambridge Limited 用於治疗疼痛的 vap-1 抑制剂
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
AU2019234574A1 (en) 2018-03-12 2020-09-03 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
WO2022253167A1 (en) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
AU2022357057A1 (en) * 2021-10-01 2024-04-11 Yuhan Corporation Bicyclic fused ring derivative or salt thereof and pharmaceutical composition comprising same
EP4436957A1 (en) 2021-11-24 2024-10-02 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
TW202340212A (zh) 2021-11-24 2023-10-16 美商建南德克公司 治療性化合物及其使用方法
WO2023193790A1 (en) * 2022-04-08 2023-10-12 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019821A1 (en) * 1999-09-14 2001-03-22 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists
US20080176892A1 (en) * 2005-04-25 2008-07-24 Timo Heinrich Novel Azaheterocyclic Compounds as Kinase Inhibitors
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8712191A (en) * 1990-10-15 1992-05-20 Byk Gulden Lomberg Chemische Fabrik Gmbh New diazines
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
ES2309206T3 (es) 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
TWI317360B (en) 2001-11-07 2009-11-21 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
US7456169B2 (en) 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
US20050096360A1 (en) 2003-08-08 2005-05-05 Salter-Cid Luisa M. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
BRPI0612112A8 (pt) * 2005-06-22 2017-12-26 Chemocentryx Inc composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.
WO2007120528A2 (en) 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
CN103497184A (zh) 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
AR063531A1 (es) 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
EP2102170A2 (en) 2006-12-06 2009-09-23 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2124568A1 (en) * 2007-01-17 2009-12-02 Merck & Co., Inc. Decahydroquinoline analogs as cb2 receptor modulators
US20110021543A1 (en) 2007-05-02 2011-01-27 Noelle Gauvry Heterocyclic compounds and their use as pesticides
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
MX2010007661A (es) 2008-01-31 2010-08-03 Sanofi Aventis Azaindol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos.
EP2334672B1 (en) 2008-09-16 2013-11-20 Proximagen Limited 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO
US8633318B2 (en) * 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
US20120010188A1 (en) 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
JP2012211085A (ja) * 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019821A1 (en) * 1999-09-14 2001-03-22 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists
US20080176892A1 (en) * 2005-04-25 2008-07-24 Timo Heinrich Novel Azaheterocyclic Compounds as Kinase Inhibitors
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074854A (zh) * 2014-09-17 2017-08-18 普罗克斯马根有限公司 咪唑并[4，5‑c]吡啶衍生的SSAO抑制剂
CN107074853A (zh) * 2014-09-17 2017-08-18 普罗克斯马根有限公司 咪唑并[4,5‑c]吡啶衍生的SSAO抑制剂
CN107074854B (zh) * 2014-09-17 2019-07-19 普罗克斯马根有限责任公司 咪唑并[4，5-c]吡啶衍生的SSAO抑制剂
CN107074853B (zh) * 2014-09-17 2019-07-23 普罗克斯马根有限责任公司 咪唑并[4，5-c]吡啶衍生的SSAO抑制剂
CN106045876A (zh) * 2016-06-07 2016-10-26 四川福思达生物技术开发有限责任公司 一种对氯苯肼盐酸盐的合成方法
CN106045876B (zh) * 2016-06-07 2018-02-09 四川福思达生物技术开发有限责任公司 一种对氯苯肼盐酸盐的合成方法
CN110325533A (zh) * 2016-09-16 2019-10-11 生命医药有限责任公司 Menin-mll相互作用的抑制剂
CN110325533B (zh) * 2016-09-16 2025-11-04 生命医药有限责任公司 Menin-mll相互作用的抑制剂

Also Published As

Publication number Publication date
ZA201206424B (en) 2013-06-26
EP2547677A2 (en) 2013-01-23
EP2927233A1 (en) 2015-10-07
EA023038B1 (ru) 2016-04-29
GB201004311D0 (en) 2010-04-28
US20130102587A1 (en) 2013-04-25
DK2547677T3 (en) 2015-06-01
KR20130057971A (ko) 2013-06-03
JP2013529179A (ja) 2013-07-18
MX2012010292A (es) 2013-03-12
EP2547677B1 (en) 2015-05-06
WO2011113798A3 (en) 2011-11-17
US9227967B2 (en) 2016-01-05
BR112012023315A2 (pt) 2016-05-24
AU2011229267B2 (en) 2013-07-18
NZ602141A (en) 2014-09-26
JP5643347B2 (ja) 2014-12-17
CA2793125A1 (en) 2011-09-22
ES2538526T3 (es) 2015-06-22
JP2015017141A (ja) 2015-01-29
EA201290880A1 (ru) 2013-03-29
AU2011229267A1 (en) 2012-09-20
WO2011113798A2 (en) 2011-09-22
SG183936A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
CN103180319A (zh) 氨基脲敏感性胺氧化酶抑制剂
US10766897B2 (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
CN103547580B (zh) 取代的稠合三环化合物、其组合物及医药用途
TWI508964B (zh) 3,5-di-substituted phenynyl compounds and salts thereof
CN103797012A (zh) 新的酶抑制剂化合物
CN105263934B (zh) 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
US9150574B2 (en) Enzyme inhibitor compounds
JP2020519589A (ja) Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2017101796A1 (zh) 酞嗪酮衍生物、其制备方法及用途
TW201033209A (en) 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof
CN115611888A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
HK1185074A (en) Inhibitors of semicarabazide - sensitive amine oxidase
CN115703783A (zh) 吡咯并嘧啶类衍生物及其制备方法和用途
HK1196610A (en) New enzyme inhibitor compounds
HK1195065A (en) New enzyme inhibitor compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185074

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130626

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1185074

Country of ref document: HK